82.67
-1.51 (-1.79%)
-1.51 (-1.79%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 144,001 |
|
|||||
| News | (2) | ||||||
| Day High | 85.585 | Low High |
|||||
| Day Low | 81.68 | ||||||
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Enanta Pharmaceuticals Inc | ENTA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| -1.51 | -1.79% | 82.67 | 19:50:07 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 84.91 | 81.68 | 85.585 | 82.67 | 84.18 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,833 | 144,001 | $ 82.98 | $ 11,949,017 | - | 40.32 - 102.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:03:24 | 3 | $ 82.67 | USD |
Period:
Draw Mode:
Enanta Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.68B | 20.32M | 16.03M | $ 97.07M | $ -79.00M | -3.91 | -21.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -8.87k | 5.90% |
Enanta Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ENTA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 86.04 | 92.90 | 81.68 | 87.81 | 337,024 | -3.37 | -3.92% |
| 1 Month | 96.64 | 102.00 | 73.71 | 88.52 | 263,634 | -13.97 | -14.46% |
| 3 Months | 55.82 | 102.00 | 53.59 | 78.11 | 187,221 | 26.85 | 48.1% |
| 6 Months | 46.12 | 102.00 | 40.37 | 62.62 | 172,388 | 36.55 | 79.25% |
| 1 Year | 42.29 | 102.00 | 40.32 | 56.37 | 156,780 | 40.38 | 95.48% |
| 3 Years | 80.73 | 107.00 | 38.40 | 63.61 | 181,579 | 1.94 | 2.4% |
| 5 Years | 31.99 | 127.77 | 25.92 | 64.31 | 192,787 | 50.68 | 158.42% |
Enanta Pharmaceuticals Description
| Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. |
